CD20 Protein, Human, Recombinant (His & Avi)

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 465.00
500 μg	5 days	$ 1,850.00
1 mg	5 days	$ 3,100.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 465.00

500 μg

5 days

$ 1,850.00

1 mg

5 days

$ 3,100.00

Description

Species	Human
Expression System	E. coli
Tag	C-His-Avi
Accession Number	P11836-1
Synonyms	MS4A2, Ly-44, LEU-16, MS4A1, Bp35, CD20 receptor, CVID5, MS4A-1, B1, S7, CD20S7, CD20
Construction	Recombinant Human CD20/MS4A1 Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. It contains Ile141-Ser188.[Accession \|P11836-1]
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	The protein has a predicted MW of 16.8 kDa same as Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in 20mM PB, 10% Glycerol, 0.4M Urea, 1mM GSH, 0.1mM GSSG (pH 7.0).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.